Back to top
more

Arcutis Biotherapeutics (ARQT)

(Real Time Quote from BATS)

$15.05 USD

15.05
260,253

-0.28 (-1.79%)

Updated Aug 6, 2025 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 4.76% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -0.94% and 1.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Zacks Equity Research

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%

by Zacks Equity Research

The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

by Zacks Equity Research

Here is how Cardinal Health (CAH) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Zacks Equity Research

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Zacks Equity Research

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 66.67% and 23.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -12.10% and 1.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Incyte (INCY) Q4 Earnings Miss Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -6.54% and 2.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CRL Gears Up for Q4 Earnings: Here's What You Need to Know

by Zacks Equity Research

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

Zacks Equity Research

STE Gears Up for Q3 Earnings: Here's What You Need to Know

by Zacks Equity Research

STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.

Zacks Equity Research

ALGN Gears Up for Q4 Earnings: What Lies Ahead for the Stock?

by Zacks Equity Research

Align Technology's fourth-quarter results are likely to reflect the strength in its Systems & Services business.

Zacks Equity Research

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

by Zacks Equity Research

Here is how Addus HomeCare (ADUS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Zacks Equity Research

IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?

by Zacks Equity Research

IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.

Zacks Equity Research

Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings

by Zacks Equity Research

Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.